skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
Indication-based pricing isn’t just coming. It’s here. Drug companies have historically priced drugs equally across indications, regardless of the variation in value. But using indication-specific pricing, payers – and PBMs in particular – see a new opportunity to break the market-share dominance of several key therapeutics, boost their near-term rebate and distribution income, and re-shape traditional contracting.

Indication-Based Pricing

Download your free article pack, to discover new insights into indication-based pricing
Market access_RxScorecard_Pharmaintelligence

Read also


Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: